The Japan next generation sequencing market size was estimated at around USD 297.98 million in 2022 and it is projected to hit around USD 2,487.58 million by 2032, growing at a CAGR of 23.64% from 2023 to 2032.
Key Pointers
- By Product, the consumables segment accounted for the largest revenue share of 75% in 2022 and it is also anticipated to grow at the fastest CAGR of 24.24% from 2023 to 2032.
- By Application, the oncology segment generated the maximum market share in 2022.
- By Application, the consumer genomics segment has been anticipated to grow fastest during the forecast period.
- By Workflow, the sequencing segment accounted for the highest revenue share in 2022.
- By End-use, the academic research segment held the largest revenue share in 2022.
- By End-use, the clinical research segment is predicted to grow at the remarkable CAGR during the forecast period.
The next-generation sequencing (NGS) market in Japan stands at the forefront of genomic innovation, driving advancements in research, diagnostics, and personalized medicine. This overview aims to provide a comprehensive insight into the current state of the Japan next-generation sequencing Market, highlighting key players, market dynamics, and the transformative impact of NGS technologies across various sectors.
Get a Sample: https://www.visionresearchreports.com/report/sample/40975
Market Growth
The growth of the next-generation sequencing (NGS) market in Japan is propelled by a confluence of factors contributing to its dynamic expansion. A key driver is the increasing prevalence of genetic disorders, prompting a heightened demand for advanced genomic diagnostics and personalized medicine solutions. The collaborative efforts between academic institutions, healthcare providers, and industry stakeholders play a pivotal role in fostering innovation and driving the adoption of NGS technologies across diverse applications. The continuous evolution of sequencing platforms and bioinformatics tools, marked by technological advancements such as single-cell sequencing and long-read sequencing, enhances the accuracy and efficiency of genomic analysis. Additionally, the supportive regulatory environment in Japan, with ongoing initiatives to streamline approval processes for NGS-based diagnostics and therapies, creates a conducive atmosphere for market growth. As the NGS market addresses challenges like data standardization and ethical considerations, these obstacles present opportunities for industry players to innovate, ensuring sustained growth in this dynamic landscape. Overall, the robust growth of the NGS market in Japan is underpinned by a combination of technological progress, collaborative initiatives, and a rising awareness of the transformative potential of genomics across various sectors.
Report Scope of the Japan Next Generation Sequencing Market
| Report Coverage | Details |
| Market Size in 2022 | USD 297.98 million |
| Revenue Forecast by 2032 | USD 2,487.58 million |
| Growth rate from 2023 to 2032 | CAGR of 23.64% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
Market Dynamics
Drivers
- Technological Advancements in NGS Platforms: Continuous advancements in NGS platforms, including the incorporation of technologies such as single-cell sequencing and long-read sequencing, contribute to enhanced accuracy, throughput, and cost-effectiveness. This technological progress propels the market forward by expanding the scope and capabilities of genomic analysis.
- Government Support and Regulatory Environment: Supportive government initiatives and a conducive regulatory environment in Japan are pivotal drivers for the NGS market. Ongoing efforts to streamline approval processes for NGS-based diagnostics and therapies create an environment that encourages research, development, and the deployment of genomic technologies in healthcare.
Restraints
- Interpretation of Complex Genomic Data: While NGS provides an unprecedented amount of genomic information, the interpretation of complex data sets remains a substantial challenge. The identification of relevant genetic variations and the translation of this information into actionable insights for clinical decision-making require advanced bioinformatics tools and expertise. Bridging this gap between raw data and meaningful results is an ongoing hurdle.
- Limited Clinical Validation for Certain Applications: In specific clinical applications of NGS, there may be a lack of comprehensive validation and standardization. This limitation can impede the widespread adoption of NGS in certain diagnostic or therapeutic contexts where rigorous clinical validation is essential for regulatory approval and broad acceptance within the medical community.
Opportunities
- Expansion of NGS Applications in Healthcare: Opportunities abound in expanding the applications of NGS in healthcare, including diagnostics, prognostics, and treatment selection. Continued research into the genomic basis of diseases and the development of validated NGS-based diagnostic assays can revolutionize clinical practices, providing more precise and personalized healthcare solutions.
- Rise of Direct-to-Consumer Genomic Services: The burgeoning interest in personal genomics offers opportunities for the growth of direct-to-consumer genomic services. Companies that provide accessible and understandable genomic information directly to consumers can capitalize on the increasing public curiosity about their genetic makeup, promoting proactive health management.
Technology Insights
Based on technology, the market is segmented into whole genome sequencing, whole exome sequencing, targeted sequencing & resequencing, and others. The targeted sequencing and resequencing segment accounted for the largest revenue share in 2022 and is also anticipated to grow the fastest CAGR over the forecast period. This segment’s dominance can be due to the several advantages offered by this technology for next-generation sequencing. This is a cost-effective technique and offers actionable and clear information to physicians.
The whole genome sequencing (WGS) segment is anticipated to witness significant growth during the forecast period, owing to the wide use of WGS to combat COVID-19. For instance, in March 2022, an article published in Frontiers stated that WGS has a potential application to detect SARS-CoV-2 Infection. Moreover, it helped differentiate community-acquired infection from hospital-acquired infection among pediatric oncology patients.
Product Insights
Based on product, the market is segmented into consumables and platforms. The consumables segment accounted for the largest revenue share of 75% in 2022, and it is also anticipated to grow at the fastest CAGR of 24.24% over the forecast period. The dominance can be attributed to an increase in investment in the development of advanced genomics techniques for prevention and detection, and a decrease in sequencing costs are contributing to the growth of the NGS consumables market.
The platforms segment is anticipated to witness significant market growth over the forecast period. NGS platforms allow the implementation of a broad range of techniques, enabling scientists to address questions related to transcriptome, genome, or epigenome. These applications make the platform a preferred choice in agriculture, clinical diagnosis, research, and sustainable development.
Application Insights
Based on application, the market is segmented into oncology, HLA typing/immune system monitoring, clinical investigation, epidemiology & drug development, reproductive health, metagenomics, agrigenomics & forensics, and consumer genomics. The oncology segment accounted for the largest revenue share in 2022. This segment dominance can be due to the wide use of NGS in oncology, where gene mutations are sequenced to develop new cancer diagnostic & treatment methods. The NGS in oncology has also been aiding a better understanding of different tumor growth cell signaling pathways, which provides oncologists insights for better diagnosis and management of various forms of cancer
The consumer genomics segment has been anticipated to grow fastest during the forecast period, owing to the rapid development in personal health awareness, paternity testing, and genealogy. Several key market players are constantly working toward expanding their product portfolio by launching new products, which would further drive the segment growth. For instance, in May 2022, PerkinElmer, Inc. expanded its genome testing services by adding ultrarapid whole genome sequencing to its portfolio.
Workflow Insights
Based on workflow, the market is segmented into pre-sequencing, sequencing, and NGS data analysis. The sequencing segment accounted for the highest revenue share in 2022. This can be attributed to the availability of various platforms such as iSeq, MiniSeq, MiSeq, NextSeq, HiSeq X, & NovaSeq series from illumina and Ion Proton, PGM, & IonS5 system from Thermo Fisher Scientific for the next generation sequencing.
The NGS data analysis segment is estimated to register the fastest CAGR over the forecast period. NGS data analysis includes sequence assembly and data analysis. As terabytes of data are produced during a single run of NGS, data storage and interpretation equipment are essential to any NGS workflow. Furthermore, several recent developments for improving data analysis by the key market players are driving the segment’s growth.
End-use Insights
Based on the end-use, the market is segmented into clinical research, academic research, pharma & biotech entities, hospitals & clinics, and other users. The academic research segment held the largest revenue share in 2022. The segment’s growth can be attributed to the availability of various institutes offering on-site bioinformatics courses and training programs that enhance knowledge about various sequencing data analysis solutions, which are expected to drive the segment growth.
The clinical research segment is predicted to grow at the remarkable CAGR during the forecast period. Implementation of NGS for studying tumor heterogeneity, the discovery of new cancer-related genes, and the identification of alterations related to tumorigenesis are expected to result in significant growth of this segment.
Key Companies
- Illumina, Inc
- QIAGEN
- Thermo Fisher Scientific, Inc
- BGI
- Pacific Biosciences
- Bio Rad Laboratories
- Oxford Nanopore Technologies, Inc
- Myriad Genetics. Inc.
- Agilent Technologies, Inc
- Eurofins Scientific
Recent Developments
Astride, a significant NGS service distributor in Japan, partnered with Basepair in September 2023 to offer its visualization platform in that country.
Illumina, Inc. introduced a product for short- and long-read sequencing on a single device in March 2023 that is based on its ground-breaking Illumina Complete Long Read technology.
Agilent Technologies Inc. launched the NGS assay for comprehensive genomic profiling (CGP) in April 2023 with the goal of increasing precision oncology.
Japan Next Generation Sequencing Market Segmentations:
By Technology
- Whole Genome Sequencing
- Whole Exome Sequencing
- Targeted Sequencing & Resequencing
- DNA-based
- RNA-based
- Others
By Product
- Consumables
- Sample Preparation
- Target Enrichment
- Platforms
- Sequencing
- Data Analysis
By Application
- Oncology
- Diagnostics and Screening
- Oncology Screening
- Sporadic Cancer
- Inherited Cancer
- Companion Diagnostics
- Other Diagnostics
- Oncology Screening
- Research Studies
- Diagnostics and Screening
- Clinical Investigation
- Infectious Diseases
- Inherited Diseases
- Idiopathic Diseases
- Non-Communicable/Other Diseases
- Reproductive Health
- NIPT
- Aneuploidy
- Microdeletions
- PGT
- Newborn Genetic Screening
- Single Gene Analysis
- NIPT
- HLA Typing/Immune System Monitoring
- Metagenomics, Epidemiology & Drug Development
- Agrigenomics & Forensics
- Consumer Genomics
By Workflow
- Pre-Sequencing
- NGS Library Preparation Kits
- Semi-automated Library Preparation
- Automated Library Preparation
- Sequencing
- NGS Data Analysis
- NGS Primary Data Analysis
- NGS Secondary Data Analysis
- NGS Tertiary Data Analysis
By End-use
- Academic Research
- Clinical Research
- Hospitals & Clinics
- Pharma & Biotech Entities
- Other users